SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali
Objectives: The InVITE study, starting in August 2021, was designed to examine the immunogenicity of different vaccine regimens in several countries including the Democratic Republic of Congo, Guinea, Liberia, and Mali. Prevaccination baseline samples were used to obtain estimates of previous SARS-C...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-05-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224000560 |
| _version_ | 1797209682417287168 |
|---|---|
| author | Sylvain Laverdure Donatien Kazadi Kadidia Kone Viviane Callier Djeneba Dabitao Dehkontee Dennis Mory Cherif Haidara Sally Hunsberger Olivier Tshiani Mbaya Renee Ridzon Irini Sereti Katy Shaw-Saliba Esther Akpa Fatoumata Binta Bah Yi-Chi Barash Abdoul Habib Beavogui Jean-Luc Biampata Tyler Bonnett Shawn Brown Alissa Burkey Daouda Camara Sekou Camara Elfrida Cline-Cole Mamadou D Coulibaly Nadie Coulibaly Robin Dewar Mountaga Diallo Samba Diarra Seydou Doumbia Allison Eyler Karine Fouth Tchos Alyson Francis Louis Grue Helene Highbarger Jeroen Highbarger Augustin Mbala Ibanda Kadé Kallon Esaie Luzolu Kindombe Placide Mbala Kingebeni Cece Francis Kolié Perrine Lallemand Caeul Lim Emmanuel Lokilo Raphael Lumembe Ashley Louise McCormack Laura McNay Gael Mukendi Thierry Mukendi Jean Jacques Muyembe Kevin Newell Wissedi Njoh Isaac Balmayel Pankwa Elisabeth Pukuta Yogolelo Riziki Adam Rupert Seydou Samake Jennifer Sandrus Adama Sangare Mary Smolskis Gema Souto Adeva Randy Stevens Cheick Oumar Tangara Moctar Tounkara Meghan Trumbull-Kennedy Antoine Tshomba Mamadou Wague Shera Weyers Chris Worthington |
| author_facet | Sylvain Laverdure Donatien Kazadi Kadidia Kone Viviane Callier Djeneba Dabitao Dehkontee Dennis Mory Cherif Haidara Sally Hunsberger Olivier Tshiani Mbaya Renee Ridzon Irini Sereti Katy Shaw-Saliba Esther Akpa Fatoumata Binta Bah Yi-Chi Barash Abdoul Habib Beavogui Jean-Luc Biampata Tyler Bonnett Shawn Brown Alissa Burkey Daouda Camara Sekou Camara Elfrida Cline-Cole Mamadou D Coulibaly Nadie Coulibaly Robin Dewar Mountaga Diallo Samba Diarra Seydou Doumbia Allison Eyler Karine Fouth Tchos Alyson Francis Louis Grue Helene Highbarger Jeroen Highbarger Augustin Mbala Ibanda Kadé Kallon Esaie Luzolu Kindombe Placide Mbala Kingebeni Cece Francis Kolié Perrine Lallemand Caeul Lim Emmanuel Lokilo Raphael Lumembe Ashley Louise McCormack Laura McNay Gael Mukendi Thierry Mukendi Jean Jacques Muyembe Kevin Newell Wissedi Njoh Isaac Balmayel Pankwa Elisabeth Pukuta Yogolelo Riziki Adam Rupert Seydou Samake Jennifer Sandrus Adama Sangare Mary Smolskis Gema Souto Adeva Randy Stevens Cheick Oumar Tangara Moctar Tounkara Meghan Trumbull-Kennedy Antoine Tshomba Mamadou Wague Shera Weyers Chris Worthington |
| author_sort | Sylvain Laverdure |
| collection | DOAJ |
| description | Objectives: The InVITE study, starting in August 2021, was designed to examine the immunogenicity of different vaccine regimens in several countries including the Democratic Republic of Congo, Guinea, Liberia, and Mali. Prevaccination baseline samples were used to obtain estimates of previous SARS-CoV-2 infection in the study population. Methods: Adult participants were enrolled upon receipt of their initial COVID-19 vaccine from August 2021 to June 2022. Demographic and comorbidity data were collected at the time of baseline sample collection. SARS-CoV-2 serum anti-Spike and anti-Nucleocapsid antibody levels were measured. Results: Samples tested included 1016, 375, 663, and 776, from DRC, Guinea, Liberia, and Mali, respectively. Only 0.8% of participants reported a prior positive SARS-CoV-2 test, while 83% and 68% had anti-Spike and anti-Nucleocapsid antibodies, respectively. Conclusions: Overall SARS-CoV-2 seroprevalence was 86% over the accrual period, suggesting a high prevalence of SARS-CoV-2 infection. Low rates of prior positive test results may be explained by asymptomatic infections, limited access to SARS-CoV-2 test kits and health care, and inadequate surveillance. These seroprevalence rates are from a convenience sample and may not be representative of the population in general, underscoring the need for timely, well-conducted surveillance as part of global pandemic preparedness. |
| first_indexed | 2024-04-24T09:58:35Z |
| format | Article |
| id | doaj.art-4880684a1ab54f1c8059cdc0b84e49b3 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-24T09:58:35Z |
| publishDate | 2024-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-4880684a1ab54f1c8059cdc0b84e49b32024-04-14T04:10:12ZengElsevierInternational Journal of Infectious Diseases1201-97122024-05-01142106985SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and MaliSylvain Laverdure0Donatien Kazadi1Kadidia Kone2Viviane Callier3Djeneba Dabitao4Dehkontee Dennis5Mory Cherif Haidara6Sally Hunsberger7Olivier Tshiani Mbaya8Renee Ridzon9Irini Sereti10Katy Shaw-Saliba11Esther Akpa12Fatoumata Binta Bah13Yi-Chi Barash14Abdoul Habib Beavogui15Jean-Luc Biampata16Tyler Bonnett17Shawn Brown18Alissa Burkey19Daouda Camara20Sekou Camara21Elfrida Cline-Cole22Mamadou D Coulibaly23Nadie Coulibaly24Robin Dewar25Mountaga Diallo26Samba Diarra27Seydou Doumbia28Allison Eyler29Karine Fouth Tchos30Alyson Francis31Louis Grue32Helene Highbarger33Jeroen Highbarger34Augustin Mbala Ibanda35Kadé Kallon36Esaie Luzolu Kindombe37Placide Mbala Kingebeni38Cece Francis Kolié39Perrine Lallemand40Caeul Lim41Emmanuel Lokilo42Raphael Lumembe43Ashley Louise McCormack44Laura McNay45Gael Mukendi46Thierry Mukendi47Jean Jacques Muyembe48Kevin Newell49Wissedi Njoh50Isaac Balmayel Pankwa51Elisabeth Pukuta52Yogolelo Riziki53Adam Rupert54Seydou Samake55Jennifer Sandrus56Adama Sangare57Mary Smolskis58Gema Souto Adeva59Randy Stevens60Cheick Oumar Tangara61Moctar Tounkara62Meghan Trumbull-Kennedy63Antoine Tshomba64Mamadou Wague65Shera Weyers66Chris Worthington67Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory, Frederick, MD; Corresponding author. Tel.: 301-228-4476.Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako, Bamako, MaliClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, MDUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako, Bamako, MaliPartnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), Monrovia, LiberiaPartnership of Clinical Research in Guinea (PREGUI), Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, GuineaNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MDClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, MDNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MDNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MDNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MDNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United StatesPartnership of Clinical Research in Guinea (PREGUI), center National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, GuineaNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United StatesPartnership of Clinical Research in Guinea (PREGUI), center National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, GuineaInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaApplied Developmental Research Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaPartnership of Clinical Research in Guinea (PREGUI), center National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, GuineaPartnership of Clinical Research in Guinea (PREGUI), center National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, GuineaClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliVirus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, Maryland, United States of AmericaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaCAMRIS International, Bethesda, Maryland, United States of AmericaNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United StatesClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaVirus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, Maryland, United States of AmericaVirus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, Maryland, United States of AmericaCenter de Recherches Cliniques, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaCenter de Recherches Cliniques, Institut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoPartnership of Clinical Research in Guinea (PREGUI), center National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, GuineaVirus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, Maryland, United States of AmericaClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoLaboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory, Frederick, Maryland, United States of AmericaNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United StatesInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoHôpital Saint Joseph, Kinshasa, Democratic Republic of CongoInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoClinical Services Program, Frederick National Laboratory, Frederick, Maryland, United States of AmericaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaPartnership of Clinical Research in Guinea (PREGUI), center National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, GuineaNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United StatesClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaApplied Developmental Research Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United StatesInstitut National de Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of CongoUniversity Clinical Research Center (UCRC), University of Sciences, Techniques, and Technologies of Bamako (USTTB), Bamako, MaliClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaClinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, Maryland, United States of AmericaObjectives: The InVITE study, starting in August 2021, was designed to examine the immunogenicity of different vaccine regimens in several countries including the Democratic Republic of Congo, Guinea, Liberia, and Mali. Prevaccination baseline samples were used to obtain estimates of previous SARS-CoV-2 infection in the study population. Methods: Adult participants were enrolled upon receipt of their initial COVID-19 vaccine from August 2021 to June 2022. Demographic and comorbidity data were collected at the time of baseline sample collection. SARS-CoV-2 serum anti-Spike and anti-Nucleocapsid antibody levels were measured. Results: Samples tested included 1016, 375, 663, and 776, from DRC, Guinea, Liberia, and Mali, respectively. Only 0.8% of participants reported a prior positive SARS-CoV-2 test, while 83% and 68% had anti-Spike and anti-Nucleocapsid antibodies, respectively. Conclusions: Overall SARS-CoV-2 seroprevalence was 86% over the accrual period, suggesting a high prevalence of SARS-CoV-2 infection. Low rates of prior positive test results may be explained by asymptomatic infections, limited access to SARS-CoV-2 test kits and health care, and inadequate surveillance. These seroprevalence rates are from a convenience sample and may not be representative of the population in general, underscoring the need for timely, well-conducted surveillance as part of global pandemic preparedness.http://www.sciencedirect.com/science/article/pii/S1201971224000560SARS-CoV-2SeroprevalenceCOVID-19West AfricaInVITEVaccines |
| spellingShingle | Sylvain Laverdure Donatien Kazadi Kadidia Kone Viviane Callier Djeneba Dabitao Dehkontee Dennis Mory Cherif Haidara Sally Hunsberger Olivier Tshiani Mbaya Renee Ridzon Irini Sereti Katy Shaw-Saliba Esther Akpa Fatoumata Binta Bah Yi-Chi Barash Abdoul Habib Beavogui Jean-Luc Biampata Tyler Bonnett Shawn Brown Alissa Burkey Daouda Camara Sekou Camara Elfrida Cline-Cole Mamadou D Coulibaly Nadie Coulibaly Robin Dewar Mountaga Diallo Samba Diarra Seydou Doumbia Allison Eyler Karine Fouth Tchos Alyson Francis Louis Grue Helene Highbarger Jeroen Highbarger Augustin Mbala Ibanda Kadé Kallon Esaie Luzolu Kindombe Placide Mbala Kingebeni Cece Francis Kolié Perrine Lallemand Caeul Lim Emmanuel Lokilo Raphael Lumembe Ashley Louise McCormack Laura McNay Gael Mukendi Thierry Mukendi Jean Jacques Muyembe Kevin Newell Wissedi Njoh Isaac Balmayel Pankwa Elisabeth Pukuta Yogolelo Riziki Adam Rupert Seydou Samake Jennifer Sandrus Adama Sangare Mary Smolskis Gema Souto Adeva Randy Stevens Cheick Oumar Tangara Moctar Tounkara Meghan Trumbull-Kennedy Antoine Tshomba Mamadou Wague Shera Weyers Chris Worthington SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali International Journal of Infectious Diseases SARS-CoV-2 Seroprevalence COVID-19 West Africa InVITE Vaccines |
| title | SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali |
| title_full | SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali |
| title_fullStr | SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali |
| title_full_unstemmed | SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali |
| title_short | SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali |
| title_sort | sars cov 2 seroprevalence in vaccine naive participants from the democratic republic of congo guinea liberia and mali |
| topic | SARS-CoV-2 Seroprevalence COVID-19 West Africa InVITE Vaccines |
| url | http://www.sciencedirect.com/science/article/pii/S1201971224000560 |
| work_keys_str_mv | AT sylvainlaverdure sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT donatienkazadi sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT kadidiakone sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT vivianecallier sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT djenebadabitao sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT dehkonteedennis sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT morycherifhaidara sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT sallyhunsberger sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT oliviertshianimbaya sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT reneeridzon sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT irinisereti sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT katyshawsaliba sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT estherakpa sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT fatoumatabintabah sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT yichibarash sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT abdoulhabibbeavogui sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT jeanlucbiampata sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT tylerbonnett sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT shawnbrown sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT alissaburkey sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT daoudacamara sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT sekoucamara sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT elfridaclinecole sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT mamadoudcoulibaly sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT nadiecoulibaly sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT robindewar sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT mountagadiallo sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT sambadiarra sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT seydoudoumbia sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT allisoneyler sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT karinefouthtchos sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT alysonfrancis sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT louisgrue sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT helenehighbarger sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT jeroenhighbarger sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT augustinmbalaibanda sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT kadekallon sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT esaieluzolukindombe sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT placidembalakingebeni sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT cecefranciskolie sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT perrinelallemand sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT caeullim sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT emmanuellokilo sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT raphaellumembe sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT ashleylouisemccormack sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT lauramcnay sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT gaelmukendi sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT thierrymukendi sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT jeanjacquesmuyembe sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT kevinnewell sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT wissedinjoh sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT isaacbalmayelpankwa sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT elisabethpukuta sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT yogoleloriziki sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT adamrupert sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT seydousamake sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT jennifersandrus sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT adamasangare sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT marysmolskis sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT gemasoutoadeva sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT randystevens sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT cheickoumartangara sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT moctartounkara sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT meghantrumbullkennedy sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT antoinetshomba sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT mamadouwague sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT sheraweyers sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali AT chrisworthington sarscov2seroprevalenceinvaccinenaiveparticipantsfromthedemocraticrepublicofcongoguinealiberiaandmali |